Novo's stock rises despite guidance cut Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T Wed Th F 7 May, 2025

FDA upheaval and tariff wars are reshaping biotech’s landscape. Join Editor-in-Chief John Carroll and industry leaders as they decode Endpoints 100 survey data revealing how executives are navigating these extraordinary challenges. Where do they see opportunity, if any? Find out — sign up today.

presented by In one of the riski­est in­dus­tries — Biotech — a sure­fire way to neu­tral­ize some of that risk emerges

spotlight Live at 11 a.m.: What Vinay Prasad means for CBER, vaccines, drug approvals and more

news Biotech stocks plunge and industry figures left to wonder after Prasad's FDA appointment •  FDA picks controversial doctor Vinay Prasad as CBER director, in about-face from Marks Novo Nordisk trims growth forecast as GLP-1 compounder ban yet to go live Sarepta’s stock plummets after Prasad appointment, low Elevidys sales Marea heads to Phase 2b after updated biomarker data show CV drug’s promise

Research Associate I/II - Gene Therapy MeiraGTx New York, NY, USA Senior Drug Development Clinician Weatherden London, UK Head of Clinical Operations ModeX Therapeutics Inc. Weston, MA 02493, USA Senior Scientist, Analytical Development Precision BioSciences Durham, NC Recruit talent with Endpoints Careers Contact Meg Estacio: mestacio@endpointsnews.com

Exploring Japan as a key market for your drug? Get the roadmap — join senior Japanese leaders to hear firsthand on the regulatory and pricing dynamics behind one of the world’s top pharma markets. Sign up now.

May 12 1:30pm ET How to incorporate pragmatic design elements into your clinical studies sponsored by Flatiron May 29 10:30am ET Optimizing the clinical research workforce - An industry analysis by Parexel sponsored by Parexel Jun 03 11:00am ET Building robust health system partnerships for life sciences sponsored by Advisory Board

endpoints pharma Trump, Congress look at matching some US drug prices to costs abroad Exclusive: SEC expected to drop investigation of Illumina's $8B Grail deal Europe pledges €500M to attract global science talent Trump, FDA zero in on foreign factories to give domestic sites an edge   States sue US over plan for reorganization of federal health agencies

in case you missed it